• Je něco špatně v tomto záznamu ?

Identifying obstacles hindering the conduct of academic-sponsored trials for drug repurposing on rare-diseases: an analysis of six use cases

M. Del Álamo, C. Bührer, D. Fisher, M. Griese, P. Lingor, G. Palladini, N. Sireau, V. Hivert, L. Sangiorgi, F. Guillot, J. Halftermeyer, L. Soucková, K. Nosková, R. Demlová

. 2022 ; 23 (1) : 783. [pub] 20220915

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22024407

Grantová podpora
EJP RD COFUND-EJP N° 825575 Horizon 2020 Framework Programme

BACKGROUND: Academic-sponsored trials for rare diseases face many challenges; the present paper identifies hurdles in the set-up of six multinational clinical trials for drug repurposing, as use cases. METHODS: Six academic-sponsored multinational trials aiming to generate knowledge on rare diseases drug repurposing were used as examples to identify problems in their set-up. Coordinating investigators leading these trials provided feedback on hurdles linked to study, country, and site set up, on the basis of pre-identified categories established through the analysis of previous peer-reviewed publications. RESULTS: Administrative burden and lack of harmonization for trial-site agreements were deemed as a major hurdle. Other main identified obstacles included the following: (1) complexity and restriction on the use of public funding, especially in a multinational set up, (2) drug supply, including procurement tendering rules and country-specific requirements for drug stability, and (3) lack of harmonization on regulatory requirements to get trial approvals. CONCLUSION: A better knowledge of the non-commercial clinical research landscape and its challenges and requirements is needed to make drugs-especially those with less commercial gain-accessible to rare diseases patients. Better information about existing resources like research infrastructures, clinical research programs, and counseling mechanisms is needed to support and guide clinicians through the many challenges associated to the set-up of academic-sponsored multinational trials.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22024407
003      
CZ-PrNML
005      
20221031100254.0
007      
ta
008      
221017s2022 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s13063-022-06713-y $2 doi
035    __
$a (PubMed)36109818
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Del Álamo, Marta $u ECRIN, European Clinical Research Network Infrastructure, Paris, France. marta.delalamo@ecrin.org $1 https://orcid.org/http://orcid.org/0000000282549990
245    10
$a Identifying obstacles hindering the conduct of academic-sponsored trials for drug repurposing on rare-diseases: an analysis of six use cases / $c M. Del Álamo, C. Bührer, D. Fisher, M. Griese, P. Lingor, G. Palladini, N. Sireau, V. Hivert, L. Sangiorgi, F. Guillot, J. Halftermeyer, L. Soucková, K. Nosková, R. Demlová
520    9_
$a BACKGROUND: Academic-sponsored trials for rare diseases face many challenges; the present paper identifies hurdles in the set-up of six multinational clinical trials for drug repurposing, as use cases. METHODS: Six academic-sponsored multinational trials aiming to generate knowledge on rare diseases drug repurposing were used as examples to identify problems in their set-up. Coordinating investigators leading these trials provided feedback on hurdles linked to study, country, and site set up, on the basis of pre-identified categories established through the analysis of previous peer-reviewed publications. RESULTS: Administrative burden and lack of harmonization for trial-site agreements were deemed as a major hurdle. Other main identified obstacles included the following: (1) complexity and restriction on the use of public funding, especially in a multinational set up, (2) drug supply, including procurement tendering rules and country-specific requirements for drug stability, and (3) lack of harmonization on regulatory requirements to get trial approvals. CONCLUSION: A better knowledge of the non-commercial clinical research landscape and its challenges and requirements is needed to make drugs-especially those with less commercial gain-accessible to rare diseases patients. Better information about existing resources like research infrastructures, clinical research programs, and counseling mechanisms is needed to support and guide clinicians through the many challenges associated to the set-up of academic-sponsored multinational trials.
650    _2
$a klinické zkoušky jako téma $7 D002986
650    12
$a přehodnocení terapeutických indikací léčivého přípravku $7 D058492
650    _2
$a lidé $7 D006801
650    _2
$a organizace $7 D009938
650    12
$a vzácné nemoci $x diagnóza $x farmakoterapie $7 D035583
655    _2
$a časopisecké články $7 D016428
700    1_
$a Bührer, Christoph $u Department of Neonatology, Charité Universitätsmedizin, Berlin, Germany
700    1_
$a Fisher, Dirk $u Division of Developmental- and Neuropaediatrics, University Children's. Hospital Basel (UKBB), University of Basel, Spitalstrasse 33, Postfach, 4031, Basel, Switzerland
700    1_
$a Griese, Matthias $u Department of Pediatrics, Dr. von Hauner Children's Hospital, University. Hospital, LMU Munich, German Center for Lung Research (DZL), Lindwurmstraße 4, 80337, Munich, Germany
700    1_
$a Lingor, Paul $u Department of Neurology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany
700    1_
$a Palladini, Giovanni $u Amyloidosis Research and Treatment Center, Foundation "Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo," and Department of Molecular Medicine, University of Pavia, Pavia, Italy
700    1_
$a Sireau, Nicolas $u AKU Society, Cambridge, UK
700    1_
$a Hivert, Virginie $u EURORDIS- Rare Diseases Europe, Paris, France
700    1_
$a Sangiorgi, Luca $u Department of Medical Genetics and Skeletal Rare Diseases, IRCCS Rizzoli Orthopaedic Institute, Bologna, Italy
700    1_
$a Guillot, Florence $u ANR, French National Research Agency, Paris, France
700    1_
$a Halftermeyer, Juliane $u Inserm Transfert, Paris, France
700    1_
$a Soucková, Lenka $u ECRIN, European Clinical Research Network Infrastructure, Paris, France $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Nosková, Kristýna $u ECRIN, European Clinical Research Network Infrastructure, Paris, France $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Demlová, Regina $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
773    0_
$w MED00163187 $t Trials $x 1745-6215 $g Roč. 23, č. 1 (2022), s. 783
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36109818 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20221017 $b ABA008
991    __
$a 20221031100252 $b ABA008
999    __
$a ok $b bmc $g 1854235 $s 1175697
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 23 $c 1 $d 783 $e 20220915 $i 1745-6215 $m Trials $n Trials $x MED00163187
GRA    __
$a EJP RD COFUND-EJP N° 825575 $p Horizon 2020 Framework Programme
LZP    __
$a Pubmed-20221017

Najít záznam

Citační ukazatele

Možnosti archivace